Pay It Forward: Bridging the Gaps Between Payers and Providers to Get the Medication Your Patient Needs When They Need It for Narcolepsy and Idiopathic Hypersomnia

Program Description

Patients with narcolepsy type 1 (NT-1), narcolepsy type 2 (NT-2), and idiopathic hypersomnia (IH) have a diverse range of clinical presentations and therapeutic needs that complicate the process of diagnosis and management. Although significant advancements have been made with the recent approval of several pharmacologic agents specifically indicated for these disorders, the pursuit of insurance authorization for these strategies often leads to obstacles that limit optimal clinical implementation and corresponding patient outcomes.

To address this situation, this program utilizes an expert panel of both sleep and payor specialists to troubleshoot common payer-related considerations that clinicians can use in their day-to-day practice to help ensure patients receive the best possible care.

Target Audience

The target audience for this activity includes sleep specialists, general neurologists, nurse practitioners, physician assistants, registered nurses, and other healthcare professionals involved in the diagnosis and long-term management of patients with sleep disorders.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • Describe the role and importance of novel treatment strategies in the management of excessive daytime sleepiness (EDS) secondary to narcolepsy and IH to determine how and for whom these strategies can be best utilized
  • Identify payer-specific barriers to and potential solutions for the utilization of recently approved medications for narcolepsy and IH to increase the timely and successful procurement of treatment options
Course summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance
Course opens: 
Course expires: 

   Asim Roy, MD (Chair & Moderator)
   Medical Director,
   Ohio Sleep Medicine Institute
   Dublin, OH



   Vikas Jain, MD
   Dream Center for Sleep and Circadian Sciences
   Frisco, TX



   Maria Lopes, MD, MS 
   Former CMO
   Magellan & EmblemHealth,
   Horizon BCBS
   Cresskill, NJ



   Jeffrey Dunn, PharmD, MBA
   President & CEO
   Cooperative Benefits Group
   Salt Lake City, U

This activity is jointly provided by  Purdue University College of Pharmacy Office of Continuing Education and Professional Development (Purdue) and Efficient LLC.


Accreditation Statement

This enduring activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy Office of Continuing Education and Professional Development and Efficient LLC. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Purdue designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based, continuing education activity of Purdue University, an equal access/equal opportunity institution.  Universal Activity Number (UAN): 0018-9999-24-014-H01-P, 1.00 contact hour (0.10 CEU). Release Date: 05/10/2024 Expiration Date: 05/10/2025.
A Certificate of Participation will be given upon completion of the enduring activity enabling participants to register their credit with the appropriate licensing boards or associations.

Conflicts of Interest Disclosure Policy

To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity. 
All relevant conflicts of interest have been mitigated prior to the start of the activity.
None of the planners, reviewers, Efficient LLC staff, and Purdue University College of Pharmacy staff have relevant financial relationship(s) with ineligible companies to disclose unless listed below.
Planners’ and Managers’ Disclosures
All additional planning committee members, staff and reviewers of Efficient LLC and Purdue University College of Pharmacy have no relationships to disclose.
Faculty Disclosures
Dr. Roy reported the following financial relationships:
  • Research: Nyxoah, Signifier
  • Speakers’ Bureau: Axsome, Avadel, Harmony, Inspire Pharmaceuticals, Jazz Pharmaceuticals
Dr. Jain reported the following financial relationships:
  • Speakers’ Bureau: Jazz Pharmaceuticals, Idorsia Pharmaceuticals

Dr. Lopes has no financial relationships to disclose.

Dr. Dunn has no financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Commercial Support

This activity is supported by educational grants from Harmony Biosciences and Jazz Pharmaceuticals.

Available Credit

  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance


Please login or register to take this course.